share_log

HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Lowers Price Target to $12

Benzinga ·  Mar 19 18:32

HC Wainwright & Co. analyst Ed Arce maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and lowers the price target from $14 to $12.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment